ASTANA—The University Medical Center (UMC) Heart Center has launched Farapulse electro-pulse ablation technology, marking a significant advancement in the treatment of cardiac arrhythmia. This innovative method is the first of its kind to be implemented in Central Asia and the Commonwealth of Independent States (CIS).
According to UMC’s press service, Farapulse technology enhances treatment efficiency, safety, and recovery times compared to existing methods for managing atrial fibrillation. Atrial fibrillation is a condition that causes rapid and irregular contractions of the heart’s upper chambers.
Professor Serge Boveda from Clinique Pasteur in France and secretary of the European Heart Rhythm Association (EHRA) explained that the procedure lasts about an hour, with a recovery period of one to two days.
“This is a minimally invasive procedure. A catheter is inserted through the femoral vein and guided to the heart, where electric fields known as electroporation destroy abnormal cells while preserving nearby healthy tissue,” Dr. Boveda stated during a masterclass at UMC on September 23.
During his visit, Professor Boveda delivered a lecture on the new technology and conducted a Q&A session. He also participated in a hands-on demonstration with UMC specialists in the catheterization laboratory.
Omirbek Nuralinov, head of the Department of Interventional Arrhythmology at UMC, noted that Farapulse technology is used globally alongside cryoablation and radiofrequency ablation for treating atrial fibrillation. Kazakhstan is the first country in the region to introduce this technology at UMC clinics.
“The technology allows for adjustments to ensure it does not harm surrounding tissues while targeting only pathological areas,” Nuralinov explained.
Yuriy Pya, chairman of the UMC executive board, emphasized the importance of this technology in addressing the increasing prevalence of cardiovascular diseases.
“Cardiovascular diseases will continue to be the leading cause of death in the coming decades. This new technology is vital for our patients, especially for the 1,000 individuals who require treatment for atrial fibrillation each year,” Pya stated.
He also highlighted that this quick and easily adoptable treatment is offered free of charge to citizens through the state healthcare quota system.
With advanced training in Farapulse technology, UMC specialists are committed to providing patients with cutting-edge methods for treating cardiovascular diseases.
Related topics:
- Exploring Alternative Treatments for Atrial Fibrillation: September Is Atrial Fibrillation Awareness Month
- New Study Links Radiotherapy to Arrhythmias in Lung Cancer Patients
- Making Radiation Therapy Safer for The Heart